Transcriptomic signatures in peripheral CD4⁺T-lymphocytes may reflect melanoma staging and immunotherapy responsiveness prior to ICI initiation.

ABSTRACT:

Background and purpose

Promoting adaptive immunity with ICIs has drastically improved melanoma prognosis, but not for all patients. Some cases relapse in the first few months, while others keep durable benefit, even after immunotherapy discontinuation. To identify cellular/molecular signatures in peripheral blood that could differentiate advanced from metastatic melanoma and predict dynamics for primary/secondary immune escape, we examined 100 consecutive patients with stage III/IV melanoma scheduled to start ICIs.

Materials and methods

At melanoma diagnosis, a multiparameter flow cytometric analysis and purification scheme using standard conjugated antibodies were performed for all individuals prior to ICI initiation. In each stage(III/IV) according to their RFS/PFS, we ret

SUBMITTER: Palli E 

PROVIDER: S-EPMC11986426 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature